effect of supplementation in treatment of diabetic hemodialysis patients

The effect of Q10 supplementation on metabolic profile, inflammatory marker and oxidative stress in diabetic hemodialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016081811763N30

Enrollment

Registered

2017-01-24

Start date

2017-02-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemodialysis. Chronic kidney disease

Interventions

Intervention 1: 60 mg coenzyme Q10, twice a day, for 3 month orally. Intervention 2: Placebo, twice a day, for 3 month orally.

Treatment - Drugs

Placebo

60 mg coenzyme Q10, twice a day, for 3 month orally

Placebo, twice a day, for 3 month orally

Eligibility

Sex/Gender

All

Age

45 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1- hemodialysis patients with glomerular filtration rate less than 10 or 25 ml/min with malnutrition and hypercalemy. 2- aged 45-75. 3-average blood pressure (systolic pressure 140-160 mmHg , diastolic pressure 90-100 mmHg) 4-diabetic patients according to American diabetes assossiation criteria. Exclusion criteria: 1-unwilling to cooperate 2- hyperthyroidism and hypothyroidism 3-specific disease leading to bed. 4-malignant hypertension (systolic pressure more than 160 mmHg and diastolic pressure more than 100mmHg)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Insulin. Timepoint: At the beginning of the study and after 3 month intervention. Method of measurement: ELISA kit - µIU/ml.;Fasting blood sample. Timepoint: At the beginning of the study and after 3 month intervention. Method of measurement: ensymatic - mg/dl.;HOMA-IR. Timepoint: At the beginning of the study and after 3 month intervention. Method of measurement: calculation.;QUICKI. Timepoint: At the beginning of the study and after 3 month intervention. Method of measurement: calculation.;HOMA-B. Timepoint: At the beginning of the study and after 3 month intervention. Method of measurement: calculation.;HbA1C. Timepoint: At the beginning of the study and after 3 month intervention. Method of measurement: calculation - percentage.	—

Measure

Time frame

Insulin. Timepoint: At the beginning of the study and after 3 month intervention. Method of measurement: ELISA kit - µIU/ml.;Fasting blood sample. Timepoint: At the beginning of the study and after 3 month intervention. Method of measurement: ensymatic - mg/dl.;HOMA-IR. Timepoint: At the beginning of the study and after 3 month intervention. Method of measurement: calculation.;QUICKI. Timepoint: At the beginning of the study and after 3 month intervention. Method of measurement: calculation.;HOMA-B. Timepoint: At the beginning of the study and after 3 month intervention. Method of measurement: calculation.;HbA1C. Timepoint: At the beginning of the study and after 3 month intervention. Method of measurement: calculation - percentage.

—

Secondary

Measure	Time frame
Nitric oxide. Timepoint: At the beginning of the study and after 3 month of intervention. Method of measurement: Spectrophotometry.;Hs-CRP. Timepoint: At the beginning of the study and after 3 month of intervention. Method of measurement: ELISA kit.;TAC. Timepoint: At the beginning of the study and after 3 month of intervention. Method of measurement: Spectrophotometry.;GSH. Timepoint: At the beginning of the study and after 3 month of intervention. Method of measurement: Spectrophotometry.;HDL. Timepoint: At the beginning of the study and after 3 month of intervention. Method of measurement: Ensymatic.;Cholestrol. Timepoint: At the beginning of the study and after 3 month of intervention. Method of measurement: Ensymatic.;TG. Timepoint: At the beginning of the study and after 3 month of intervention. Method of measurement: Ensymatic.;MDA. Timepoint: At the beginning of the study and after 3 month of intervention. Method of measurement: Spectrophotometry.	—

Measure

Time frame

Nitric oxide. Timepoint: At the beginning of the study and after 3 month of intervention. Method of measurement: Spectrophotometry.;Hs-CRP. Timepoint: At the beginning of the study and after 3 month of intervention. Method of measurement: ELISA kit.;TAC. Timepoint: At the beginning of the study and after 3 month of intervention. Method of measurement: Spectrophotometry.;GSH. Timepoint: At the beginning of the study and after 3 month of intervention. Method of measurement: Spectrophotometry.;HDL. Timepoint: At the beginning of the study and after 3 month of intervention. Method of measurement: Ensymatic.;Cholestrol. Timepoint: At the beginning of the study and after 3 month of intervention. Method of measurement: Ensymatic.;TG. Timepoint: At the beginning of the study and after 3 month of intervention. Method of measurement: Ensymatic.;MDA. Timepoint: At the beginning of the study and after 3 month of intervention. Method of measurement: Spectrophotometry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Science

asemi_r@yahoo.com+98 3155540021712

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 5, 2026